Japan tops CPhI ‘API Quality’ ranking for second year
Tokyo, 11 March 2022: CPhI Japan 2022 returns as a SMART event – with live exhibition at the Big Sight Exhibition Center in Tokyo (20-22 April) alongside an online networking platform – as CPhI data confirms the country continues to top global ‘API quality’ rankings, with Japanese respondents bullish on growth in 2022 forecasting a CAGR of 14% on average. The country, despite the global challenges of the last year, also increased its ‘overall competitiveness’ score by 2%, while ranking narrowly behind only Germany and the USA for the quality of its ‘finished product manufacturing’ (8.28) and ‘innovativeness for solid dose’ (7.39).
“Interest from international audiences about how to enter Japan and find regional suppliers and manufacturers remains extremely strong. Demand for generics in particular continues to grow, with companies looking for stable supply chains and alternative suppliers, which is why international interest in networking is so strong. In fact, alongside the matchmaking program, we have an international seminar program addressing the opportunities and challenges when looking to enter Asia’s second largest pharma market,” commented Laura Murina, Brand Manager, Informa Markets.
To enable international audiences to fully capitalize, the 2022 edition is running as a SMART event with interactive networking features, replicating the onsite experience, alongside the online content platform. It has been designed to give attendees the maximum opportunity to connect, learn and grow.
CPhI Japan is expected to welcome 16,000 pharma professionals and executives and 300+ exhibitors from 25+ countries. Online attendees, as well as exhibitors and visitors, are able to use the digital matchmaking system from March 15th, and online meetings are available to be held for the majority of April (from the 4th through until the 28th).
Emphasizing the increasing demand and outsourcing challenges ahead, Japan has a number of covid vaccines approaching commercial launch at the same time as an ongoing biosimilars boom. Consequently, competition for partners and supply chain resources is increasing quickly, and more than 60% of Japanese companies state their potential partners are ‘approaching them much earlier than before’ according to the CPhI data. Murina, added, “what we have seen globally, and has been even more true in Japan, is that companies are looking at diversifying their supply chains and increasing resilience – naturally this means meeting and pre-auditing new partners. It’s why our online platforms have proved so popular in markets like Japan where it's vital international attendees make new contacts and start building networks,”
Further accentuating the move to digital pharma partnering, 100% of Japanese respondents to the CPhI survey stated they expected ‘remote facilities monitoring to become the standard approach’ over the next 2-3 years.
CPhI Japan will also host a conference with 200+ sessions including online English language seminars exploring ‘API trend outlook 2022’ headlined by Aurelio Arias, Engagement Manager, IQVIA and ‘Measuring the Covid-19 effect on clinical trials’ presented by Daniel Chancellor, Thought Leadership and Consulting Director, Pharma Intelligence, Informa. Keynote Sessions feature ‘Covid-19s impact on R&D for 2022’ presented by Ian Haydock, Editor-in-Chief, APAC, Pharma Intelligence, Informa plc and ‘Environmental sustainability in pharma’ from Alan Thomas, Director, Thought Leadership, IQVIA Japan Group.
CPhI Japan covers the entire pharmaceutical supply chain with four collocated events: ICSE, PMEC, bioLIVE and InnoPack. For more information and to register to attend, please visit: https://www.cphi.com/japan/en/home.html and https://www.informa-japan.com/cphifcj/form/en/visitor_regist.php
Notes to editors
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; and Finished Dosage Formulation for every aspect of the finished dosage supply chain. CPhI provides an online buyer and supplier directory at CPhI-Online.com.
For more information visit https://www.cphi.com
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
For more information, please visit www.informamarkets.com.
CPhI Japan (20-22 April, 2022 at the Big Sight Exhibition Centre – Tokyo, Japan); CPhI North America (17-19 May, 2022 at Pennsylvania Convention Center, United States), Pharmapack Europe (18-19 May 2022 at Paris Expo, Porte de Versailles - Hall 7.2, Paris); CPhI & P-MEC China (21-23 June, 2021 at SNIEC – Shanghai, China); CPhI South East Asia (19-21 Oct 2022 at IMPACT, Thailand); CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (01-03 November 2022 at Messe Frankfurt, Frankfurt); CPhI & P-MEC India (29 November – 1st December 2022 at the India Expo Mart, Greater Noida, Delhi NCR – Delhi, India)
For media enquiries, please contact:
Abdul Khalifeh or Alex Heeley
De Facto Communications
M: +44 (0) 746 331 7575
T: +44 (0) 203 735 8165
 Scoring just over eight out of ten, and above all other countries – CPhI Annual Survey data